A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering

作者：Leusink Maarten; Maitland van der Zee Anke H; Ding Bo; Drenos Fotios; van Iperen Erik P A; Warren Helen R; Caulfield Mark J; Cupples L Adrienne; Cushman Mary; Hingorani Aroon D; Hoogeveen Ron C; Hovingh G Kees; Kumari Meena; Lange Leslie A; Munroe Patricia B; Nyberg Fredrik; Schreiner Pamela J; Sivapalaratnam Suthesh; de Bakker Paul I W; de Boer Anthonius; Keating Brendan J; Asselbergs Folkert W; Onland Moret N Charlotte^*

来源：Pharmacogenomics, 2016, 17(6): 583-591.

DOI：10.2217/pgs.16.8

• pharmacogenetics cholesterol
• risk score
• statin therapy

Aim: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome. Patients & methods: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up associations with p < 1 x 10(-4) (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE. Results: No new SNPs were found associated with statin response. The GRS was associated with reduced statin response: 0.0394 mmol/l per allele (95% CI: 0.0171-0.0617, p = 5.37 x 10(-4)). Conclusion: The GRS was associated with statin response, but the small effect size (similar to 2% of the average low-density lipoprotein cholesterol reduction) limits applicability.

• 出版日期2016-4
• 单位河北医科大学